NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

NEW YORK CITY, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. Receive News & Ratings for Valneva Daily - Enter your ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Analysts expect Valneva to post earnings of ($0.22) per share and revenue of $55.64 million for the quarter. Valneva Trading Up 0.1 % NASDAQ VALN opened at $6.80 on Monday.

A preliminary study has found that efavirenz — a non-nucleoside inhibitor of HIV virus that is used for treating HIV/AIDS — can be repurposed for the treatment of chikungunya. Currently ...

Chikungunya infections began to increase by the end of September 2022 in Paraguay, which declared on Feb. 24 that it was on alert due to the “atypical clinical and epidemiological behavior” of ...

New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme ...

After hours: March 14 at 4:00:09 p.m. EDT Loading Chart for VALN ...

GLUE Monte Rosa Therapeutics, Inc.